Byron Michael Berenger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Byron Michael Berenger has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Nathan Zelyas
Alberta Precision Laboratories, Calgary, Canada
6 shared publicationsGraham Tipples
Public Health Laboratory, Alberta Precision Laboratories , Edmonton, Alberta
5 shared publicationsJia Hu
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
4 shared publications- Kanti Pabbaraju
Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada
4 shared publications Kevin Fonseca
Public Health Laboratory, Alberta Precision Laboratories, Calgary , Alberta
4 shared publications- William Stokes
Alberta Precision Laboratories
4 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (10)
Reducing inappropriate infectious disease serology tests through the use of decision support in a provincial electronic health system
Diagnostic stewardship improves patient care and reduces health costs by promoting appropriate test use. Ordering serologic tests for infectious diseases can be challenging, with indications differing based on the clinical picture, previous results, or pathogens. We aimed to use our electronic health system (EHS) to provide real-time, patient-specific education on test appropriateness to reduce inappropriate testing. This observational study took place from October 2023 to 2024. The study included all users of the province-wide, integrated EHS in Alberta, Canada (population 4.9 million), which captures all laboratory orders across healthcare settings. Two diagnostic stewardship measures were assessed for 23 infectious disease serology tests: (i) Best Practice Advisories (BPAs) triggered at the point of ordering tests, and (ii) auto-cancellation rules that canceled the test upon receipt of the sample at the testing laboratory. BPAs flagged duplicate orders (within 3 days for IgM and 7 days for IgG), previously positive IgG, or missing prerequisite tests. Providers could override BPAs if necessary. After 1 year, BPAs led to 22,907 canceled tests (1.4% of targeted tests ordered). An additional 90,749 (5.3%) tests were auto-canceled upon laboratory receipt. Clinicians overrode BPAs on only 146 occasions (0.6%), with no signal of alert fatigue. BPAs prevented an estimated 16,744 phlebotomies and saved $52,049 CAD ($38,516 USD) in laboratory reagents. Auto-cancellation rules saved an additional $208,089 CAD ($153,986 USD). Integrating BPAs into an EHS effectively supports diagnostic stewardship at ordering by reducing unnecessary phlebotomies, improving test selection, and saving resources. When electronic ordering is unavailable, auto-cancellations upon laboratory receipt are an effective alternative. IMPORTANCE: Serology tests for past or current infections are among the most ordered laboratory investigations, yet a substantial proportion are unnecessary, particularly when patients have had recent testing or known immunity. Unneeded testing wastes resources, exposes patients to avoidable blood draws, and can produce misleading results that trigger further investigations. This study shows that two simple tools built into a province-wide electronic health record can meaningfully reduce inappropriate ordering of serologic tests across a wide range of viral and bacterial pathogens. Across nearly 1.7 million tests in 1 year, the interventions canceled more than 113,000 unnecessary tests, prevented thousands of blood draws, lowered carbon emissions, and saved roughly a quarter million Canadian dollars in laboratory reagents alone. As these tools require no additional personnel or infrastructure, the approach is widely applicable to clinical laboratories regardless of size or resource setting, supporting broader adoption of electronic decision support for efficient infection testing.
- 14 October 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (10)
Open AccessReducing inappropriate infectious disease serology tests through the use of decision support in a provincial electronic health system
Diagnostic stewardship improves patient care and reduces health costs by promoting appropriate test use. Ordering serologic tests for infectious diseases can be challenging, with indications differing based on the clinical picture, previous results, or pathogens. We aimed to use our electronic health system (EHS) to provide real-time, patient-specific education on test appropriateness to reduce inappropriate testing. This observational study took place from October 2023 to 2024. The study included all users of the province-wide, integrated EHS in Alberta, Canada (population 4.9 million), which captures all laboratory orders across healthcare settings. Two diagnostic stewardship measures were assessed for 23 infectious disease serology tests: (i) Best Practice Advisories (BPAs) triggered at the point of ordering tests, and (ii) auto-cancellation rules that canceled the test upon receipt of the sample at the testing laboratory. BPAs flagged duplicate orders (within 3 days for IgM and 7 days for IgG), previously positive IgG, or missing prerequisite tests. Providers could override BPAs if necessary. After 1 year, BPAs led to 22,907 canceled tests (1.4% of targeted tests ordered). An additional 90,749 (5.3%) tests were auto-canceled upon laboratory receipt. Clinicians overrode BPAs on only 146 occasions (0.6%), with no signal of alert fatigue. BPAs prevented an estimated 16,744 phlebotomies and saved $52,049 CAD ($38,516 USD) in laboratory reagents. Auto-cancellation rules saved an additional $208,089 CAD ($153,986 USD). Integrating BPAs into an EHS effectively supports diagnostic stewardship at ordering by reducing unnecessary phlebotomies, improving test selection, and saving resources. When electronic ordering is unavailable, auto-cancellations upon laboratory receipt are an effective alternative. IMPORTANCE: Serology tests for past or current infections are among the most ordered laboratory investigations, yet a substantial proportion are unnecessary, particularly when patients have had recent testing or known immunity. Unneeded testing wastes resources, exposes patients to avoidable blood draws, and can produce misleading results that trigger further investigations. This study shows that two simple tools built into a province-wide electronic health record can meaningfully reduce inappropriate ordering of serologic tests across a wide range of viral and bacterial pathogens. Across nearly 1.7 million tests in 1 year, the interventions canceled more than 113,000 unnecessary tests, prevented thousands of blood draws, lowered carbon emissions, and saved roughly a quarter million Canadian dollars in laboratory reagents alone. As these tools require no additional personnel or infrastructure, the approach is widely applicable to clinical laboratories regardless of size or resource setting, supporting broader adoption of electronic decision support for efficient infection testing.
- Open Access
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Improving isolate recovery and identification of the Shiga toxin type in Shiga toxin nucleic acid test-positive feces
Infections caused by Shiga toxin-producing Escherichia coli (STEC) strains carrying Shiga toxin 2 ( stx 2) are more likely to result in severe complications; however, most nucleic acid amplification tests used for STEC diagnosis do not differentiate between stx 1 and stx 2. We therefore sought to optimize stx typing and isolate recovery methods to guide clinical and public health management. stx polymerase chain reaction (PCR)-positive feces were cultured using CHROMagar STEC and gram-negative broth, with Stx1 and/or Stx2 antigen detection by enzyme immunoassay (EIA) on colony growth or turbid broth. When cultures were EIA-negative, growth from MacConkey agar (MAC), Trypticase soy broth, and the gram-negative broth was then tested using a lab-developed typing PCR for stx 1 and stx 2. Colonies were isolated on CHROMagar STEC or MAC and identified using the typing PCR. Using both EIA and typing PCR, the stx types were identified in 96.0% of cases (381/397). In 65.2% (259/397) of cases, culture was EIA-positive, of which 34.0% (87/256) were Stx2-positive. Among cultures that were EIA-negative but typing PCR-positive, 64.8% (79/122) were stx 2-positive ( P < 0.0001 compared to EIA-positive). Using both EIA and typing PCR resulted in 72.6% (286/394) of cases with successful attempts at isolate recovery, compared to 60.7% (239/394) with EIA alone. E. coli O157 was recovered from more EIA-positive cases (19.3%, 46/239) than EIA-negative ones (4.3%, 2/47) ( P = 0.0097). Typing PCR on cultures improves stx typing (particularly stx 2) and isolate detection compared to EIA alone. Screening BD Max PCR and subsequent typing PCR results showed excellent concordance. IMPORTANCE: Escherichia coli strains with one or both types of Shiga toxins ( stx1 and stx2 ) are a common cause of bacterial diarrhea and can lead to serious complications such as kidney failure, especially in children. Infection by stx2 -positive strains is more likely to do so. Therefore, knowing whether the infection is caused by a strain carrying stx2 is important for risk assessment and case follow-up. The conventional way to diagnose these infections is to grow the bacteria from stool, but most laboratories currently use nucleic acid detection (e.g., bacterial DNA detection by polymerase chain reaction [PCR]), and these assays do not differentiate between the two toxin genes. Culture is therefore required to determine toxin type, as well as for public health outbreak investigations, which require an isolate for whole-genome sequencing for serotyping and cluster analysis. We identified culture media and a PCR-based method to detect stx2 in culture that improved the detection of stx2 and isolate recovery. Our findings provide more accurate results for clinicians to improve patient care and tools for public health teams to control and prevent outbreaks.
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Open AccessImproving isolate recovery and identification of the Shiga toxin type in Shiga toxin nucleic acid test-positive feces
Infections caused by Shiga toxin-producing Escherichia coli (STEC) strains carrying Shiga toxin 2 ( stx 2) are more likely to result in severe complications; however, most nucleic acid amplification tests used for STEC diagnosis do not differentiate between stx 1 and stx 2. We therefore sought to optimize stx typing and isolate recovery methods to guide clinical and public health management. stx polymerase chain reaction (PCR)-positive feces were cultured using CHROMagar STEC and gram-negative broth, with Stx1 and/or Stx2 antigen detection by enzyme immunoassay (EIA) on colony growth or turbid broth. When cultures were EIA-negative, growth from MacConkey agar (MAC), Trypticase soy broth, and the gram-negative broth was then tested using a lab-developed typing PCR for stx 1 and stx 2. Colonies were isolated on CHROMagar STEC or MAC and identified using the typing PCR. Using both EIA and typing PCR, the stx types were identified in 96.0% of cases (381/397). In 65.2% (259/397) of cases, culture was EIA-positive, of which 34.0% (87/256) were Stx2-positive. Among cultures that were EIA-negative but typing PCR-positive, 64.8% (79/122) were stx 2-positive ( P < 0.0001 compared to EIA-positive). Using both EIA and typing PCR resulted in 72.6% (286/394) of cases with successful attempts at isolate recovery, compared to 60.7% (239/394) with EIA alone. E. coli O157 was recovered from more EIA-positive cases (19.3%, 46/239) than EIA-negative ones (4.3%, 2/47) ( P = 0.0097). Typing PCR on cultures improves stx typing (particularly stx 2) and isolate detection compared to EIA alone. Screening BD Max PCR and subsequent typing PCR results showed excellent concordance. IMPORTANCE: Escherichia coli strains with one or both types of Shiga toxins ( stx1 and stx2 ) are a common cause of bacterial diarrhea and can lead to serious complications such as kidney failure, especially in children. Infection by stx2 -positive strains is more likely to do so. Therefore, knowing whether the infection is caused by a strain carrying stx2 is important for risk assessment and case follow-up. The conventional way to diagnose these infections is to grow the bacteria from stool, but most laboratories currently use nucleic acid detection (e.g., bacterial DNA detection by polymerase chain reaction [PCR]), and these assays do not differentiate between the two toxin genes. Culture is therefore required to determine toxin type, as well as for public health outbreak investigations, which require an isolate for whole-genome sequencing for serotyping and cluster analysis. We identified culture media and a PCR-based method to detect stx2 in culture that improved the detection of stx2 and isolate recovery. Our findings provide more accurate results for clinicians to improve patient care and tools for public health teams to control and prevent outbreaks.
- Open Access
- 19 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e826-e835
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests (RPOCTs): An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
Background: In July 2019, a syphilis outbreak was declared in Alberta, Canada, affecting key populations. Syphilis rapid/point-of-care testing (RPOCT) provides opportunities to test individuals in nontraditional settings and provide same-day treatment. This study aimed to evaluate whether RPOCT resulted in a decline in new syphilis positivity rates. Methods: Starting August 2020, syphilis RPOCTs were implemented in a single (Edmonton) health zone (EDM phase) and in March 2022 were scaled up across the province of Alberta (ProvScaleUp phase). To evaluate the impact of RPOCTs on new syphilis positivity rates, interrupted time-series analyses were used to analyze population-standardized new syphilis positivity rates before, during, and after RPOCT implementation. Generalized linear models assessed percentage declines in new syphilis positivity rates after RPOCT implementation. Results: In the preintervention period, monthly new syphilis positivity rates significantly increased across Alberta. After RPOCTs were implemented regionally (EDM phase), syphilis positivity rates decreased by an average of 15% (0.25 per 100 000 population). After wider distribution (ProvScaleUp phase), provincial rates decreased by 25% (0.22 per 100 000 population). Rates decreased more in the general versus prenatal population (15.9% vs 12.2%), among males versus females (16.0% vs 14.5%), among those in metropolitan versus urban and rural areas (15.2%, 14.0%, and 12.2%, respectively) and decreased the least among those aged 24–29 (12.5%). Conclusions: Syphilis RPOCT implementation was associated with a significant decrease in new syphilis positivity rates in a province of a high-income country experiencing a resurgence of heterosexual syphilis among key populations facing barriers to testing and treatment.
- 19 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e826-e835
Open AccessEvaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests (RPOCTs): An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
Background: In July 2019, a syphilis outbreak was declared in Alberta, Canada, affecting key populations. Syphilis rapid/point-of-care testing (RPOCT) provides opportunities to test individuals in nontraditional settings and provide same-day treatment. This study aimed to evaluate whether RPOCT resulted in a decline in new syphilis positivity rates. Methods: Starting August 2020, syphilis RPOCTs were implemented in a single (Edmonton) health zone (EDM phase) and in March 2022 were scaled up across the province of Alberta (ProvScaleUp phase). To evaluate the impact of RPOCTs on new syphilis positivity rates, interrupted time-series analyses were used to analyze population-standardized new syphilis positivity rates before, during, and after RPOCT implementation. Generalized linear models assessed percentage declines in new syphilis positivity rates after RPOCT implementation. Results: In the preintervention period, monthly new syphilis positivity rates significantly increased across Alberta. After RPOCTs were implemented regionally (EDM phase), syphilis positivity rates decreased by an average of 15% (0.25 per 100 000 population). After wider distribution (ProvScaleUp phase), provincial rates decreased by 25% (0.22 per 100 000 population). Rates decreased more in the general versus prenatal population (15.9% vs 12.2%), among males versus females (16.0% vs 14.5%), among those in metropolitan versus urban and rural areas (15.2%, 14.0%, and 12.2%, respectively) and decreased the least among those aged 24–29 (12.5%). Conclusions: Syphilis RPOCT implementation was associated with a significant decrease in new syphilis positivity rates in a province of a high-income country experiencing a resurgence of heterosexual syphilis among key populations facing barriers to testing and treatment.
- Open Access
- 1 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0022725
Bacterial gastroenteritis in the world of culture-independent diagnostic testing: a study to evaluate the kinetics of bacterial shedding by culture and CIDT
Reliable microbiological diagnosis is important for patient and public health management of bacterial gastroenteritis. Clinical laboratories are adopting culture-independent diagnostic tests (CIDT) widely. We examined the kinetics of bacterial shedding by CIDT and culture following an episode of acute gastroenteritis with one of three prevalent pathogens. The primary outcome was the proportion of samples that tested CIDT-positive or culture-positive at defined time intervals after clinical diagnosis. This longitudinal observational study was conducted in Calgary Health Zone (Alberta, Canada) between 2019 and 2022. Eligible adult patients (≥18 years) were consented and enrolled after a routine public health investigation. Stool samples were submitted at weeks 2, 3, 4, 5, and 6 post-diagnosis. Stools were tested using the commercial nucleic acid-based BD MAX Enteric Bacterial Panel (CIDT method) and routine culture methods. Thirty-seven of 83 enrolled individuals (45%) submitted at least one additional stool. Diagnostic specimens were positive for Campylobacter ( n = 19), Salmonella ( n = 8), and Shiga toxin-producing Escherichia coli (STEC, n = 10). Median duration of CIDT positivity was 42, 29, and 22 days for Campylobacter, Salmonella, and STEC, respectively. Median duration of culture positivity was 29, 29, and 19.5 days, respectively. Differences between CIDT and culture positivity over time were not statistically significant for Campylobacter ( P = 0.23), Salmonella ( P = 0.89), and STEC ( P = 0.20). A negative CIDT result was 100% predictive of a culture-negative result. Comparing CIDT and culture, no differences in shedding were found between methods in this pilot study. Further larger studies would help better understand the kinetics of CIDT positivity and clinical implications. IMPORTANCE: This study contributes to the limited literature comparing the shedding of common bacterial enteropathogens by culture-independent diagnostic testing (CIDT) methods in comparison to conventional culture. Many clinical microbiology laboratories have implemented CIDT methods for screening stool specimens due to the slower turnaround times and variable sensitivity of culture. Public health agencies often require a negative culture for return-to-work clearance in special situations or sensitive occupations, including food handlers. In our study, we demonstrated that there were no significant differences in the duration of shedding between test methods for three common bacterial pathogens, Campylobacter , Salmonella, and Shiga toxin-producing Escherichia coli . Furthermore, a negative CIDT result was 100% predictive of a negative culture result. This study contributes to the growing body of literature documenting the clinical and public health utility of CIDT in bacterial gastroenteritis.
- 1 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0022725
Open AccessBacterial gastroenteritis in the world of culture-independent diagnostic testing: a study to evaluate the kinetics of bacterial shedding by culture and CIDT
Reliable microbiological diagnosis is important for patient and public health management of bacterial gastroenteritis. Clinical laboratories are adopting culture-independent diagnostic tests (CIDT) widely. We examined the kinetics of bacterial shedding by CIDT and culture following an episode of acute gastroenteritis with one of three prevalent pathogens. The primary outcome was the proportion of samples that tested CIDT-positive or culture-positive at defined time intervals after clinical diagnosis. This longitudinal observational study was conducted in Calgary Health Zone (Alberta, Canada) between 2019 and 2022. Eligible adult patients (≥18 years) were consented and enrolled after a routine public health investigation. Stool samples were submitted at weeks 2, 3, 4, 5, and 6 post-diagnosis. Stools were tested using the commercial nucleic acid-based BD MAX Enteric Bacterial Panel (CIDT method) and routine culture methods. Thirty-seven of 83 enrolled individuals (45%) submitted at least one additional stool. Diagnostic specimens were positive for Campylobacter ( n = 19), Salmonella ( n = 8), and Shiga toxin-producing Escherichia coli (STEC, n = 10). Median duration of CIDT positivity was 42, 29, and 22 days for Campylobacter, Salmonella, and STEC, respectively. Median duration of culture positivity was 29, 29, and 19.5 days, respectively. Differences between CIDT and culture positivity over time were not statistically significant for Campylobacter ( P = 0.23), Salmonella ( P = 0.89), and STEC ( P = 0.20). A negative CIDT result was 100% predictive of a culture-negative result. Comparing CIDT and culture, no differences in shedding were found between methods in this pilot study. Further larger studies would help better understand the kinetics of CIDT positivity and clinical implications. IMPORTANCE: This study contributes to the limited literature comparing the shedding of common bacterial enteropathogens by culture-independent diagnostic testing (CIDT) methods in comparison to conventional culture. Many clinical microbiology laboratories have implemented CIDT methods for screening stool specimens due to the slower turnaround times and variable sensitivity of culture. Public health agencies often require a negative culture for return-to-work clearance in special situations or sensitive occupations, including food handlers. In our study, we demonstrated that there were no significant differences in the duration of shedding between test methods for three common bacterial pathogens, Campylobacter , Salmonella, and Shiga toxin-producing Escherichia coli . Furthermore, a negative CIDT result was 100% predictive of a negative culture result. This study contributes to the growing body of literature documenting the clinical and public health utility of CIDT in bacterial gastroenteritis.
- Open Access
- 22 March 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-13
Patient and ward related risk factors in a multi-ward nosocomial outbreak of COVID-19: Outbreak investigation and matched case–control study
Background: Risk factors for nosocomial COVID-19 outbreaks continue to evolve. The aim of this study was to investigate a multi-ward nosocomial outbreak of COVID-19 between 1st September and 15th November 2020, occurring in a setting without vaccination for any healthcare workers or patients. Methods: Outbreak report and retrospective, matched case–control study using incidence density sampling in three cardiac wards in an 1100-bed tertiary teaching hospital in Calgary, Alberta, Canada. Patients were confirmed/probable COVID-19 cases and contemporaneous control patients without COVID-19. COVID-19 outbreak definitions were based on Public Health guidelines. Clinical and environmental specimens were tested by RT-PCR and as applicable quantitative viral cultures and whole genome sequencing were conducted. Controls were inpatients on the cardiac wards during the study period confirmed to be without COVID-19, matched to outbreak cases by time of symptom onset dates, age within ± 15 years and were admitted in hospital for at least 2 days. Demographics, Braden Score, baseline medications, laboratory measures, co-morbidities, and hospitalization characteristics were collected on cases and controls. Univariate and multivariate conditional logistical regression was used to identify independent risk factors for nosocomial COVID-19. Results: The outbreak involved 42 healthcare workers and 39 patients. The strongest independent risk factor for nosocomial COVID-19 (IRR 3.21, 95% CI 1.47–7.02) was exposure in a multi-bedded room. Of 45 strains successfully sequenced, 44 (97.8%) were B.1.128 and differed from the most common circulating community lineages. SARS-CoV-2 positive cultures were detected in 56.7% (34/60) of clinical and environmental specimens. The multidisciplinary outbreak team observed eleven contributing events to transmission during the outbreak. Conclusions: Transmission routes of SARS-CoV-2 in hospital outbreaks are complex; however multi-bedded rooms play a significant role in the transmission of SARS-CoV-2.
- 22 March 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-13
Open AccessPatient and ward related risk factors in a multi-ward nosocomial outbreak of COVID-19: Outbreak investigation and matched case–control study
Background: Risk factors for nosocomial COVID-19 outbreaks continue to evolve. The aim of this study was to investigate a multi-ward nosocomial outbreak of COVID-19 between 1st September and 15th November 2020, occurring in a setting without vaccination for any healthcare workers or patients. Methods: Outbreak report and retrospective, matched case–control study using incidence density sampling in three cardiac wards in an 1100-bed tertiary teaching hospital in Calgary, Alberta, Canada. Patients were confirmed/probable COVID-19 cases and contemporaneous control patients without COVID-19. COVID-19 outbreak definitions were based on Public Health guidelines. Clinical and environmental specimens were tested by RT-PCR and as applicable quantitative viral cultures and whole genome sequencing were conducted. Controls were inpatients on the cardiac wards during the study period confirmed to be without COVID-19, matched to outbreak cases by time of symptom onset dates, age within ± 15 years and were admitted in hospital for at least 2 days. Demographics, Braden Score, baseline medications, laboratory measures, co-morbidities, and hospitalization characteristics were collected on cases and controls. Univariate and multivariate conditional logistical regression was used to identify independent risk factors for nosocomial COVID-19. Results: The outbreak involved 42 healthcare workers and 39 patients. The strongest independent risk factor for nosocomial COVID-19 (IRR 3.21, 95% CI 1.47–7.02) was exposure in a multi-bedded room. Of 45 strains successfully sequenced, 44 (97.8%) were B.1.128 and differed from the most common circulating community lineages. SARS-CoV-2 positive cultures were detected in 56.7% (34/60) of clinical and environmental specimens. The multidisciplinary outbreak team observed eleven contributing events to transmission during the outbreak. Conclusions: Transmission routes of SARS-CoV-2 in hospital outbreaks are complex; however multi-bedded rooms play a significant role in the transmission of SARS-CoV-2.
- Open Access
- 16 November 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1-11
A pragmatic randomized controlled trial of rapid on-site influenza and respiratory syncytial virus PCR testing in paediatric and adult populations
Background: Rapid/point-of-care respiratory virus nucleic acid tests (NAT) may improve oseltamivir, antibiotic, diagnostic test, and hospital bed utilization. Previous randomized controlled trials (RCT) on this topic have not used standard procedures of an accredited healthcare and laboratory system. Methods: We conducted a parallel RCT at two hospitals [paediatric = Alberta Children’s Hospital (ACH); primarily adult = Peter Lougheed Centre (PLC)]. Patients with a respiratory viral testing order were randomized to testing at either a central accredited laboratory (standard arm) or with a rapid polymerase chain reaction test at an on-site accredited laboratory followed by standard testing [rapid on-site test (ROST) arm] based on day of specimen receipt at the laboratory. Patients and clinicians were blinded to assignment. The primary outcome for ACH was inpatient length of stay (LOS) and for PLC was the proportion of inpatients prescribed oseltamivir. Results: 706 patient encounters were included at ACH; 322 assigned to ROST (181 inpatients) and 384 to the standard arm (194 inpatients). 422 patient encounters were included at PLC; 200 assigned to ROST (157 inpatients) and 222 to the standard arm (175 inpatients). The rate of oseltamivir prescription and number of doses given was reduced in PLC inpatients negative for influenza in the ROST arm compared to standard arm [mean 14.9% (95% CI 9.87–21.9) vs. 27.5% (21.0–35.2), p = 0.0135; mean 2.85 doses (SEM 2.39–3.32) vs. 4.17 doses (3.85–4.49) p = 0.022, respectively]. ROST also significantly reduced oseltamivir use at ACH, reduced chest radiographs (ACH), and laboratory test ordering (PLC), but not antibiotic prescriptions. ROST also reduced the median turnaround time by > 24 h (ACH and PLC). The LOS at ACH was not significantly different between the ROST and standard arms [median 4.05 days (SEM 1.79–18.2) vs 4.89 days (2.07–22.9), p = 0.062, respectively]. No adverse events were reported. Conclusions: In a RCT representing implementation of ROST in an accredited laboratory system, we found that a ROST improved oseltamivir utilization and is the first RCT to show reduced ancillary testing in both paediatric and adult populations. A larger study is required to assess reduction in paediatric LOS as ACH was underpowered. These findings help justify the implementation of rapid on-site respiratory virus testing for inpatients. Trial registration ISRCTN, number 10110119, Retrospectively Registered, 01/12/2021.
- 16 November 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1-11
Open AccessA pragmatic randomized controlled trial of rapid on-site influenza and respiratory syncytial virus PCR testing in paediatric and adult populations
Background: Rapid/point-of-care respiratory virus nucleic acid tests (NAT) may improve oseltamivir, antibiotic, diagnostic test, and hospital bed utilization. Previous randomized controlled trials (RCT) on this topic have not used standard procedures of an accredited healthcare and laboratory system. Methods: We conducted a parallel RCT at two hospitals [paediatric = Alberta Children’s Hospital (ACH); primarily adult = Peter Lougheed Centre (PLC)]. Patients with a respiratory viral testing order were randomized to testing at either a central accredited laboratory (standard arm) or with a rapid polymerase chain reaction test at an on-site accredited laboratory followed by standard testing [rapid on-site test (ROST) arm] based on day of specimen receipt at the laboratory. Patients and clinicians were blinded to assignment. The primary outcome for ACH was inpatient length of stay (LOS) and for PLC was the proportion of inpatients prescribed oseltamivir. Results: 706 patient encounters were included at ACH; 322 assigned to ROST (181 inpatients) and 384 to the standard arm (194 inpatients). 422 patient encounters were included at PLC; 200 assigned to ROST (157 inpatients) and 222 to the standard arm (175 inpatients). The rate of oseltamivir prescription and number of doses given was reduced in PLC inpatients negative for influenza in the ROST arm compared to standard arm [mean 14.9% (95% CI 9.87–21.9) vs. 27.5% (21.0–35.2), p = 0.0135; mean 2.85 doses (SEM 2.39–3.32) vs. 4.17 doses (3.85–4.49) p = 0.022, respectively]. ROST also significantly reduced oseltamivir use at ACH, reduced chest radiographs (ACH), and laboratory test ordering (PLC), but not antibiotic prescriptions. ROST also reduced the median turnaround time by > 24 h (ACH and PLC). The LOS at ACH was not significantly different between the ROST and standard arms [median 4.05 days (SEM 1.79–18.2) vs 4.89 days (2.07–22.9), p = 0.062, respectively]. No adverse events were reported. Conclusions: In a RCT representing implementation of ROST in an accredited laboratory system, we found that a ROST improved oseltamivir utilization and is the first RCT to show reduced ancillary testing in both paediatric and adult populations. A larger study is required to assess reduction in paediatric LOS as ACH was underpowered. These findings help justify the implementation of rapid on-site respiratory virus testing for inpatients. Trial registration ISRCTN, number 10110119, Retrospectively Registered, 01/12/2021.
- 28 July 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (8) , 849-856
The use of drones for the delivery of diagnostic test kits and medical supplies to remote First Nations communities during Covid-19
- 28 July 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (8) , 849-856
The use of drones for the delivery of diagnostic test kits and medical supplies to remote First Nations communities during Covid-19
- Open Access
- 6 June 2022
- Published by Springer Nature in Research Square
A Pragmatic Randomized Controlled Trial of Rapid On-site Influenza and Respiratory Syncytial Virus PCR Testing in Paediatric and Adult Populations
Background Rapid/point-of-care respiratory virus nucleic acid tests (NAT) may improve oseltamivir utilization and decrease length of stay (LOS) in hospital. Previous randomized controlled trials (RCT) on this topic have not used standard procedures of an accredited healthcare and laboratory system. MethodsWe conducted a parallel RCT at two hospitals (paediatric = Alberta Children’s Hospital [ACH]; primarily adult = Peter Lougheed Centre [PLC]). Patients with a respiratory viral testing order were randomized to testing at either a central accredited laboratory (standard arm) or with a rapid polymerase chain reaction test at an on-site accredited laboratory followed by standard testing (rapid on-site test [ROST] arm) based on day of specimen receipt at the laboratory. Patients and clinicians were blinded to assignment. The primary outcome for ACH was inpatient LOS and for PLC was the proportion of inpatients prescribed oseltamivir. Results 706 patient encounters were included at ACH; 322 assigned to ROST (181 inpatients) and 384 to the standard arm (194 inpatients). 422 patient encounters were included at PLC; 200 assigned to ROST (157 inpatients) and 222 to the standard arm (175 inpatients).The LOS at ACH was not significantly different between the ROST and standard arms (median 4.05 days (SEM 1.79-18.2) vs 4.89 days (2.07-22.9), p=0.062, respectively). The rate of oseltamivir prescription and number of doses given was reduced in PLC inpatients negative for influenza in the ROST arm compared to standard arm (mean 14.8% (95% CI 9.80-21.8) vs. 27.5% (21.0-35.2), p=0.0093; mean 2.85 doses (SEM 2.39-3.32) vs. 4.17 doses (3.85-4.49) p=0.022, respectively). ROST also significantly reduced oseltamivir use at ACH, reduced chest radiographs (ACH) and laboratory test ordering (PLC), but not antibiotic prescriptions. No adverse events were reported. ConclusionsIn a RCT representing implementation of ROST in an accredited laboratory system, we found that a ROST improved oseltamivir utilization and is the first RCT to show reduced ancillary testing in both paediatric and adult populations. A larger study is required to assess reduction in paediatric LOS as ACH was underpowered. These findings help justify the implementation of rapid on-site respiratory virus testing for inpatients. Trial Registration: ISRCTN10110119, Retrospectively Registered, 01/12/2021.
- 6 June 2022
- Published by Springer Nature in Research Square
Open AccessA Pragmatic Randomized Controlled Trial of Rapid On-site Influenza and Respiratory Syncytial Virus PCR Testing in Paediatric and Adult Populations
Background Rapid/point-of-care respiratory virus nucleic acid tests (NAT) may improve oseltamivir utilization and decrease length of stay (LOS) in hospital. Previous randomized controlled trials (RCT) on this topic have not used standard procedures of an accredited healthcare and laboratory system. MethodsWe conducted a parallel RCT at two hospitals (paediatric = Alberta Children’s Hospital [ACH]; primarily adult = Peter Lougheed Centre [PLC]). Patients with a respiratory viral testing order were randomized to testing at either a central accredited laboratory (standard arm) or with a rapid polymerase chain reaction test at an on-site accredited laboratory followed by standard testing (rapid on-site test [ROST] arm) based on day of specimen receipt at the laboratory. Patients and clinicians were blinded to assignment. The primary outcome for ACH was inpatient LOS and for PLC was the proportion of inpatients prescribed oseltamivir. Results 706 patient encounters were included at ACH; 322 assigned to ROST (181 inpatients) and 384 to the standard arm (194 inpatients). 422 patient encounters were included at PLC; 200 assigned to ROST (157 inpatients) and 222 to the standard arm (175 inpatients).The LOS at ACH was not significantly different between the ROST and standard arms (median 4.05 days (SEM 1.79-18.2) vs 4.89 days (2.07-22.9), p=0.062, respectively). The rate of oseltamivir prescription and number of doses given was reduced in PLC inpatients negative for influenza in the ROST arm compared to standard arm (mean 14.8% (95% CI 9.80-21.8) vs. 27.5% (21.0-35.2), p=0.0093; mean 2.85 doses (SEM 2.39-3.32) vs. 4.17 doses (3.85-4.49) p=0.022, respectively). ROST also significantly reduced oseltamivir use at ACH, reduced chest radiographs (ACH) and laboratory test ordering (PLC), but not antibiotic prescriptions. No adverse events were reported. ConclusionsIn a RCT representing implementation of ROST in an accredited laboratory system, we found that a ROST improved oseltamivir utilization and is the first RCT to show reduced ancillary testing in both paediatric and adult populations. A larger study is required to assess reduction in paediatric LOS as ACH was underpowered. These findings help justify the implementation of rapid on-site respiratory virus testing for inpatients. Trial Registration: ISRCTN10110119, Retrospectively Registered, 01/12/2021.
- 25 January 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 203, 114018
Bi-ECDAQ: An electrochemical dual-immuno-biosensor accompanied by a customized bi-potentiostat for clinical detection of SARS-CoV-2 Nucleocapsid proteins
- 25 January 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 203, 114018
Bi-ECDAQ: An electrochemical dual-immuno-biosensor accompanied by a customized bi-potentiostat for clinical detection of SARS-CoV-2 Nucleocapsid proteins
- Open Access
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 195-201
Performance of four commercial real-time PCR assays for the detection of bacterial enteric pathogens in clinical samples
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 195-201
Open AccessPerformance of four commercial real-time PCR assays for the detection of bacterial enteric pathogens in clinical samples